Logo image of APVO

APTEVO THERAPEUTICS INC (APVO) Stock Fundamental Analysis

NASDAQ:APVO - Nasdaq - US03835L4059 - Common Stock - Currency: USD

0.3099  0 (-0.03%)

After market: 0.3218 +0.01 (+3.84%)

Fundamental Rating

2

Taking everything into account, APVO scores 2 out of 10 in our fundamental rating. APVO was compared to 561 industry peers in the Biotechnology industry. While APVO seems to be doing ok healthwise, there are quite some concerns on its profitability. APVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

APVO had negative earnings in the past year.
APVO had a negative operating cash flow in the past year.
APVO had negative earnings in 4 of the past 5 years.
In the past 5 years APVO always reported negative operating cash flow.
APVO Yearly Net Income VS EBIT VS OCF VS FCFAPVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -167.24%, APVO is not doing good in the industry: 85.74% of the companies in the same industry are doing better.
APVO has a Return On Equity of -559.13%. This is amonst the worse of the industry: APVO underperforms 80.57% of its industry peers.
Industry RankSector Rank
ROA -167.24%
ROE -559.13%
ROIC N/A
ROA(3y)-32.3%
ROA(5y)-41.16%
ROE(3y)-812.67%
ROE(5y)-577.31%
ROIC(3y)N/A
ROIC(5y)N/A
APVO Yearly ROA, ROE, ROICAPVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APVO Yearly Profit, Operating, Gross MarginsAPVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

APVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
APVO has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, APVO has less shares outstanding
APVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APVO Yearly Shares OutstandingAPVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
APVO Yearly Total Debt VS Total AssetsAPVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -27.46, we must say that APVO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of APVO (-27.46) is worse than 90.37% of its industry peers.
There is no outstanding debt for APVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.46
ROIC/WACCN/A
WACC5.91%
APVO Yearly LT Debt VS Equity VS FCFAPVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 1.77 indicates that APVO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.77, APVO is doing worse than 78.79% of the companies in the same industry.
APVO has a Quick Ratio of 1.77. This is a normal value and indicates that APVO is financially healthy and should not expect problems in meeting its short term obligations.
APVO has a worse Quick ratio (1.77) than 77.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.77
APVO Yearly Current Assets VS Current LiabilitesAPVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for APVO have decreased strongly by -713.99% in the last year.
EPS 1Y (TTM)-713.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1237.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

APVO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.93% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.95%
EPS Next 2Y40.43%
EPS Next 3Y25.59%
EPS Next 5Y14.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
APVO Yearly Revenue VS EstimatesAPVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2027 2028 2029 2030 2031 2032 20M 40M 60M
APVO Yearly EPS VS EstimatesAPVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20K -40K -60K -80K -100K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

APVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year APVO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APVO Price Earnings VS Forward Price EarningsAPVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APVO Per share dataAPVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300 -400 -500

4.3 Compensation for Growth

APVO's earnings are expected to grow with 25.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.43%
EPS Next 3Y25.59%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for APVO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APTEVO THERAPEUTICS INC

NASDAQ:APVO (5/20/2025, 8:00:00 PM)

After market: 0.3218 +0.01 (+3.84%)

0.3099

0 (-0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06
Earnings (Next)08-06 2025-08-06
Inst Owners3.33%
Inst Owner Change-59.56%
Ins Owners0.01%
Ins Owner Change0%
Market Cap1.81M
Analysts82.86
Price Target21.42 (6811.91%)
Short Float %8.82%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.53%
Min EPS beat(2)24.06%
Max EPS beat(2)75%
EPS beat(4)4
Avg EPS beat(4)50.06%
Min EPS beat(4)24.06%
Max EPS beat(4)75%
EPS beat(8)7
Avg EPS beat(8)46.78%
EPS beat(12)10
Avg EPS beat(12)71.86%
EPS beat(16)11
Avg EPS beat(16)39.02%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-89.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-530.07
EYN/A
EPS(NY)-16.16
Fwd EYN/A
FCF(TTM)-4.15
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0
BVpS0.76
TBVpS0.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -167.24%
ROE -559.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.3%
ROA(5y)-41.16%
ROE(3y)-812.67%
ROE(5y)-577.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.77
Altman-Z -27.46
F-Score4
WACC5.91%
ROIC/WACCN/A
Cap/Depr(3y)21.85%
Cap/Depr(5y)15.73%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-713.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1237.18%
EPS Next Y96.95%
EPS Next 2Y40.43%
EPS Next 3Y25.59%
EPS Next 5Y14.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-39.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-40.37%
OCF growth 3YN/A
OCF growth 5YN/A